Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Condition:   Advanced, Persistent, or Recurrent Endometrial CancerInterventions:   Drug: Everolimus;   Drug: Tamoxifen;   Drug: Letrozole;   Drug: Medroxyprogesterone AcetateSponsors:   Gynecologic Oncology Group;   Novartis PharmaceuticalsNot yet recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2014 Category: Research Source Type: clinical trials

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Condition:   Advanced, Persistent, or Recurrent Endometrial CancerInterventions:   Drug: Everolimus;   Drug: Tamoxifen;   Drug: Letrozole;   Drug: Medroxyprogesterone AcetateSponsors:   Gynecologic Oncology Group;   Novartis PharmaceuticalsNot yet recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2014 Category: Research Source Type: clinical trials

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
Condition:   Prostate CancerInterventions:   Biological: DCVAC/PCa;   Drug: Leuprolide acetate;   Drug: Goserelin AcetateSponsor:   Sotio a.s.Active, not recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2014 Category: Research Source Type: clinical trials

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Enzalutamide;   Drug: Leuprolide acetate;   Radiation: radiationSponsors:   University of Texas Southwestern Medical Center;   Astellas Pharma US, Inc.Recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 10, 2014 Category: Research Source Type: clinical trials

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Enzalutamide;   Drug: Leuprolide acetate;   Radiation: radiationSponsors:   University of Texas Southwestern Medical Center;   Astellas Pharma US, Inc.Recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 10, 2014 Category: Research Source Type: clinical trials

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Enzalutamide;   Drug: Leuprolide acetate;   Radiation: radiationSponsors:   University of Texas Southwestern Medical Center;   Astellas Pharma US, Inc.Recruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 10, 2014 Category: Research Source Type: clinical trials

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Conditions:   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate CancerInterventions:   Drug: Enzalutamide;   Drug: Goserelin acetate;   Drug: Leuprolide acetate;   Radiation: Radiation therapySponsors:   Thomas Jefferson University;   Astellas Pharma Inc;   Medivation, Inc.Recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2013 Category: Research Source Type: clinical trials

A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer.
Condition:   Prostatic NeoplasmInterventions:   Drug: Metformin;   Drug: PlaceboSponsor:   AHS Cancer Control AlbertaRecruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2013 Category: Research Source Type: clinical trials

1303GCC: Trastuzmab & Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC
Condition:   Metastatic Breast CancerInterventions:   Drug: Trastuzumab plus Pertuzumab;   Drug: Hormonal Therapy with Anastrozole and Fulvestrant;   Drug: Chemotherapy with EribulinSponsors:   Katherine Tkaczuk;   Genentech, Inc.Recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2013 Category: Research Source Type: clinical trials

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy
Condition:   Prostate CancerIntervention:   Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Radiation Therapy Oncology GroupActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2013 Category: Research Source Type: clinical trials

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
Condition:   Breast CancerInterventions:   Other: Sample collection;   Behavioral: Patient-reported outcomesSponsor:   Sidney Kimmel Comprehensive Cancer CenterRecruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2013 Category: Research Source Type: clinical trials

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
Condition:   Breast CancerInterventions:   Other: Sample collection;   Behavioral: Patient-reported outcomesSponsor:   Sidney Kimmel Comprehensive Cancer CenterRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 3, 2013 Category: Research Source Type: clinical trials

Development of a Quantitative Tissue Optical Index of Breast Density For Prediction of Hormone Therapy Response
Condition:   Accessory; Breast TissueIntervention:   Other: Breast DensitySponsors:   Montana Compton;   University of California, San Francisco;   University of California, IrvineRecruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2013 Category: Research Source Type: clinical trials

Development of a Quantitative Tissue Optical Index of Breast Density For Prediction of Hormone Therapy Response
Condition:   Accessory; Breast TissueIntervention:   Other: Breast DensitySponsors:   University of California, Irvine;   University of California, San Francisco;   Beckman Laser Institute University of California IrvineRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 14, 2013 Category: Research Source Type: clinical trials

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Condition:   Prostate CancerIntervention:   Drug: Triptorelin 11.25 mgSponsor:   IpsenRecruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2012 Category: Research Source Type: clinical trials

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Condition:   Prostate CancerIntervention:   Drug: Triptorelin 11.25 mgSponsor:   IpsenRecruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2012 Category: Research Source Type: clinical trials

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Condition:   Prostate CancerIntervention:   Drug: Triptorelin 11.25 mgSponsor:   IpsenRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2012 Category: Research Source Type: clinical trials

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
Condition:   Prostate CancerIntervention:   Drug: Triptorelin 11.25 mgSponsor:   IpsenRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2012 Category: Research Source Type: clinical trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysisSponsors:   University of Washington;   National Cancer Institute (NCI)Active, not re...
Source: ClinicalTrials.gov - November 1, 2012 Category: Research Source Type: clinical trials